Endocrine FGF23 regulates phosphate and vitamin D homeostasis by reducing the cell surface expression of sodium phosphate co-transporters and by repressing transcription of rate-limiting enzymes for vitamin D biosynthesis 1,2 in the kidney. FGF23 exerts its metabolic functions by binding and activating FGFR tyrosine kinases 3 in an α -klotho co-receptor dependent fashion. The extracellular domain of a prototypical FGFR consists of three immunoglobulin-like domains: D1, D2 and D3. The membrane proximal portion comprising D2, D3 and the D2-D3 linker (FGFR ecto ) is both necessary and sufficient for FGF ligand binding 4,5 . Tissue-specific alternative splicing in the D3 domain of FGFR1-FGFR3 generates 'b' and 'c' isoforms, each with distinct ligand-binding specificity 5,6 . α -klotho, fortuitously discovered as an ageing-suppressor gene 7 , is a single-pass transmembrane protein with an extracellular domain composed of two tandem domains (KL1 and KL2), each with notable homology to family 1 glycosidases 8 (Extended Data Fig. 1a ). Membrane-bound α -klotho (α -klotho TM ) associates with cognate FGFRs of FGF23, namely the 'c' splice isoforms of . This enables them to bind and respond to FGF23 9,11,12 . α -klotho TM is predominantly expressed in the kidney distal tubules, the parathyroid gland, and the brain choroid plexus 7,13 , and this is considered to determine the target tissue specificity of FGF23 11,12 . Cleavage of α -klotho TM by ADAM proteases 14,15 in kidney distal tubules sheds the α -klotho ectodomain (α -klotho ecto ; Extended Data Fig. 1a ) into body fluids, for example, serum, urine and cerebrospinal fluid [16][17][18][19] . α -Klotho ecto is thought to lack co-receptor activity and act as a circulating anti-ageing hormone independently of FGF23 20,21 . A plethora of activities has been attributed to shed α -klotho ecto , the bulk of which require a purported intrinsic glycosidase activity [22][23][24][25] . Here we show that circulating α -klotho ecto is an on-demand bona fide co-receptor for FGF23, and determine its crystal structure in complex with FGFR1c ecto and FGF23. The structure reveals that α -klotho serves as a non-enzymatic scaffold that simultaneously tethers FGFR1c and FGF23 to implement FGF23-FGFR1c proximity and hence stability. Surprisingly, heparan sulfate (HS), a mandatory cofactor for paracrine FGFs, is still required as an ancillary cofactor to promote the formation of a symmetric 2:2:2:2 FGF23-FGFR1c-Klotho-HS quaternary signalling complex.
Endocrine FGF23 regulates phosphate and vitamin D homeostasis by reducing the cell surface expression of sodium phosphate co-transporters and by repressing transcription of rate-limiting enzymes for vitamin D biosynthesis 1,2 in the kidney. FGF23 exerts its metabolic functions by binding and activating FGFR tyrosine kinases 3 in an α -klotho co-receptor dependent fashion. The extracellular domain of a prototypical FGFR consists of three immunoglobulin-like domains: D1, D2 and D3. The membrane proximal portion comprising D2, D3 and the D2-D3 linker (FGFR ecto ) is both necessary and sufficient for FGF ligand binding 4, 5 . Tissue-specific alternative splicing in the D3 domain of FGFR1-FGFR3 generates 'b' and 'c' isoforms, each with distinct ligand-binding specificity 5, 6 . α -klotho, fortuitously discovered as an ageing-suppressor gene 7 , is a single-pass transmembrane protein with an extracellular domain composed of two tandem domains (KL1 and KL2), each with notable homology to family 1 glycosidases 8 (Extended Data Fig. 1a ). Membrane-bound α -klotho (α -klotho TM ) associates with cognate FGFRs of FGF23, namely the 'c' splice isoforms of FGFR1 and FGFR3 (FGFR1c and FGFR3c) and FGFR4 [9] [10] [11] [12] . This enables them to bind and respond to FGF23 9, 11, 12 . α -klotho TM is predominantly expressed in the kidney distal tubules, the parathyroid gland, and the brain choroid plexus 7, 13 , and this is considered to determine the target tissue specificity of FGF23 11, 12 . Cleavage of α -klotho TM by ADAM proteases 14, 15 in kidney distal tubules sheds the α -klotho ectodomain (α -klotho ecto ; Extended Data Fig. 1a ) into body fluids, for example, serum, urine and cerebrospinal fluid [16] [17] [18] [19] . α -Klotho ecto is thought to lack co-receptor activity and act as a circulating anti-ageing hormone independently of FGF23 20, 21 . A plethora of activities has been attributed to shed α -klotho ecto , the bulk of which require a purported intrinsic glycosidase activity [22] [23] [24] [25] .
Here we show that circulating α -klotho ecto is an on-demand bona fide co-receptor for FGF23, and determine its crystal structure in complex with FGFR1c ecto and FGF23. The structure reveals that α -klotho serves as a non-enzymatic scaffold that simultaneously tethers FGFR1c and FGF23 to implement FGF23-FGFR1c proximity and hence stability. Surprisingly, heparan sulfate (HS), a mandatory cofactor for paracrine FGFs, is still required as an ancillary cofactor to promote the formation of a symmetric 2:2:2:2 FGF23-FGFR1c-Klotho-HS quaternary signalling complex.
Soluble α -klotho ecto acts as a co-receptor for FGF23
To determine whether soluble α -klotho ecto can support FGF23 signalling, α -klotho-deficient HEK293 cells, which naturally express FGFRs, were incubated with a concentration of α -klotho ecto sufficient to drive all available cell-surface cognate FGFRs into binary complexed form. After brief rinses with PBS, the cells were stimulated with increasing concentrations of FGF23. In parallel, a HEK293 cell line that overexpresses membrane-bound α -klotho (HEK293-α -klotho TM ) was treated with increasing concentrations of FGF23. The doseresponse for FGF23-induced ERK phosphorylation in α -klotho ecto -pretreated untransfected HEK293 cells was similar to that observed in HEK293-α -klotho TM cells (Extended Data Fig. 1b, top) , suggesting that α -klotho ecto can serve as a co-receptor for FGF23. Pre-treatment of HEK293-α -klotho TM cells with α -klotho ecto did not result in any further increase in FGF23 signalling, indicating that all cell-surface FGFRs in this cell line were in binary FGFR-α -klotho TM form (Extended Data  Fig. 1b, bottom) . We conclude that soluble and transmembrane forms of α -klotho possess a similar capacity to support FGF23 signalling. Consistent with these results, injection of wild-type mice with α -klotho ecto protein led to an increase in renal phosphate excretion and a decrease in serum phosphate (Extended Data Fig. 1c) . Notably, it also led to a 1.5-fold increase in Egr1 transcripts in the kidney (Extended Data Fig. 1d ), demonstrating that α -klotho ecto can serve as a bona fide co-receptor to support FGF23 signalling in renal proximal tubules. In light of these data, we propose that the pleiotropic anti-ageing effects of α -klotho are all dependent on FGF23.
The ageing suppressor α-klotho binds to the fibroblast growth factor receptor (FGFR). This commits FGFR to respond to FGF23, a key hormone in the regulation of mineral ion and vitamin D homeostasis. The role and mechanism of this co-receptor are unknown. Here we present the atomic structure of a 1:1:1 ternary complex that consists of the shed extracellular domain of α-klotho, the FGFR1c ligand-binding domain, and FGF23. In this complex, α-klotho simultaneously tethers FGFR1c by its D3 domain and FGF23 by its C-terminal tail, thus implementing FGF23-FGFR1c proximity and conferring stability. Dimerization of the stabilized ternary complexes and receptor activation remain dependent on the binding of heparan sulfate, a mandatory cofactor of paracrine FGF signalling. The structure of α-klotho is incompatible with its purported glycosidase activity. Thus, shed α-klotho functions as an on-demand non-enzymatic scaffold protein that promotes FGF23 signalling.
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Structural basis of α -klotho co-receptor function
We solved the crystal structure of a human 1:1:1 FGF23-FGFR1c ecto -α -klotho ecto ternary complex at 3.0 Å resolution (Extended Data Table 1 ). In this complex, α -klotho ecto serves as a massive scaffold, tethering both FGFR1c and FGF23 to itself. In doing so, α -klotho ecto enforces FGF23-FGFR1c proximity and thus augments FGF23-FGFR1c binding affinity (Fig. 1) . The overall geometry of the ternary complex is compatible with its formation on the cell surface (Extended Data Fig. 2a) .
The binary FGF23-FGFR1c ecto complex adopts a canonical FGF-FGFR complex topology, in which FGF23 is bound between the D2 and D3 domains of the receptor, engaging both these domains and a short interdomain linker (Extended Data Fig. 3a) . However, compared to paracrine FGFs, FGF23 makes fewer or weaker contacts with the D3 domain and D2-D3 linker, explaining the inherently low affinity of FGF23 for FGFR1c (Extended Data Fig. 3b, c) . Notably, analysis of the binding interface between FGF23 and FGFR1c D3 in the crystal structure reveals specific contacts between FGF23 and a serine residue uniquely present in the 'c' splice isoforms of FGFR1-FGFR3 and in FGFR4 (Extended Data Fig. 4a ). Indeed, replacing this 'c'-isoformspecific serine residue with a 'b'-isoform-specific tyrosine impaired FGF23 signalling (Extended Data Fig. 4b, c) . We conclude that the FGFR binding specificity inherent to FGF23 operates alongside that of α -klotho (Extended Data Fig. 4d , e) to restrict FGF23 signalling to the 'c' splice isoforms and FGFR4 11, 12 .
In the ternary complex, α -klotho ecto exists in an extended conformation. Consistent with their sequence homology to the glycoside hydrolase A clan 8 , the α -klotho KL1 (Glu34 to Phe506) and KL2 (Leu515 to Ser950) domains each assume a (β α ) 8 triosephosphate isomerase (TIM) barrel fold consisting of an inner eight-stranded parallel β -barrel and eight surrounding α -helices ( Fig. 2a and Extended Data Fig. 5a ). The two KL domains are connected by a short, proline-rich and hence stiff linker (Pro507 to Pro514) (Fig. 1a, b) . KL1 sits atop KL2, engaging it via a few interdomain contacts involving the N terminus preceding the β 1 strand and the α 7 helix of KL1, and the β5α 5 and β 6α 6 loops and α 7 helix of KL2 (Extended Data Fig. 2b) . Notably, one of the interdomain contacts is mediated by a Zn 2+ ion ( Fig. 3c and Extended Data Fig. 2b, c) . These contacts stabilize the observed elongated conformation of α -klotho ecto , creating a deep cleft between the two KL domains. This merges with a wide-open central β -barrel cavity in KL2, and forms a large binding pocket that tethers the distal C-terminal tail of FGF23 past the 176-Arg-His-Thr-Arg-179 proteolytic cleavage site (Fig. 1b) . Meanwhile, the long β 1α 1 loop of KL2 (Fig. 2a) protrudes as much as 35 Å away from the KL2 core to latch onto the FGFR1c D3 domain, thus anchoring the receptor to α -klotho (Fig. 1b) . Accordingly, we have named this KL2 loop the receptor binding arm (RBA; residues 530-578; Extended Data Fig. 5a ).
We superimposed the TIM barrels of KL1 and KL2 onto that of klotho-related protein (KLrP, also known as GBA3), the cytosolic member of the klotho family with proven glycosylceramidase activity 26 . This comparison revealed major conformational differences in the loops surrounding the entrance to the catalytic pocket in KL1 and KL2 ( Fig. 2b and Extended Data Fig. 5b-d) . Moreover, both KL domains lack one of the key catalytic glutamates deep within the putative catalytic pocket. These substantial differences are incompatible with an intrinsic glycosidase activity for α -klotho [22] [23] [24] [25] . Indeed, α -klotho ecto failed to hydrolyse substrates for both sialidase and β -glucuronidase in vitro (Fig. 2c) . Together, our data define α -klotho as the only known example of a TIM barrel protein that serves purely as a non-enzymatic molecular scaffold.
Binding interface between α -klotho and FGFR1c
The interface between α -klotho RBA and FGFR1c D3 (Fig. 3a) buries over 2,200 Å 2 of solvent-exposed surface area, which is consistent with the high affinity of α -klotho binding to FGFR1c (dissociation constant (K d ) = 72 nM) 10 . At the distal tip of the RBA, residues 547-TyrLeu-Trp-549 and 556-Ile-Leu-Arg-558 form a short β -strand pair (RBA-β 1:RBA-β 2) as their hydrophobic side chains are immersed in a wide hydrophobic groove between the four-stranded β C′ -β C-β F-β G sheet and the β C-β C′ loop of FGFR1c D3 (Fig. 3b, top) . The RBA-β 1:RBA-β 2 strand pair forms an extended β -sheet with the β C′ -β C-β F-β G sheet of D3 as the backbone atoms of RBA-β 1 and D3 β C′ make three hydrogen bonds that further augment the interface (Fig. 3b, bottom) . Residues at the proximal end of the RBA engage a second smaller binding pocket at the bottom edge of D3 next to the hydrophobic groove (Extended Data Fig. 6a, b) . Both α -klotho binding pockets in the receptor D3 domain differ between 'b' and 'c' splice isoforms. Leu342, for example, is strictly conserved in the 'c' splice isoforms of FGFR1-FGFR3 and FGFR4. This explains the previously described binding selectivity of α -klotho for this subset of FGFRs 9,11,12 (Extended Data Fig. 4a ). Consistent with the crystal structure, soluble α -klotho lacking the RBA (α -klotho ecto/ΔRBA ) failed to form a binary complex with FGFR1c ecto in solution (Fig. 4a ) and hence could not support FGF23 signalling (Fig. 4b) . Likewise, membrane-bound α -klotho lacking the RBA (α -klotho TM/ΔRBA ) was also disabled in acting as a FGF23 co-receptor (Fig. 4b) . Importantly, α -klotho ecto/ΔRBA did not exhibit any phosphaturic activity in vivo (Extended Data Fig. 7a ). On the contrary, the α -klotho ecto/ΔRBA mutant antagonized the activity of native α -klotho by sequestering FGF23 into functionally inactive binary complexes, that is, by acting as an FGF23 ligand trap (Extended Data Fig. 7 ). These data refute the concept that α -klotho ecto functions as an FGF23-independent phosphaturic enzyme 24 . Our conclusion is supported by a gene knockout study that compared the phenotypes of mice with knockout of FGF23 (Fgf23 ) and double-knockout mice (Fgf23 
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Binding interface between α -klotho and FGF23
Regions from both KL domains act together to recruit FGF23 (Fig. 1b) , thus explaining why only an intact α -klotho ectodomain is capable of supporting FGF23 signalling 12, 28 . The interactions between FGF23 and α -klotho result in the burial of a large amount of solvent-exposed surface area (2,732 Å 2 ), of which nearly two-thirds (1,961 Å 2 ) are buried between the FGF23 C-terminal tail and α -klotho, and the remaining one-third is buried between the FGF23 core and α -klotho (Fig. 3a) . At the interface between α -klotho and the FGF23 C-terminal tail, FGF23 residues 188-Asp-Pro-Leu-Asn-Val-Leu-193 adopt an unusual cagelike conformation (Fig. 3a, c) , which is tethered by residues from both KL domains via hydrogen bonds and hydrophobic contacts deep inside the KL1-KL2 cleft (Fig. 3c) . Further downstream, the side chains of Lys194, Arg196 and Arg198 of the FGF23 C-terminal tail dip into the central barrel cavity of KL2, making hydrogen bonds with several α -klotho residues (Fig. 3c) . At the interface between the FGF23 β -trefoil core and α -klotho, residues from the β 5β 6 turn and the α C helix of FGF23 make hydrogen bonds and hydrophobic contacts with residues in the short β 7α 7 and β 8α 8 loops at the upper rim of the KL2 cavity (Extended Data Fig. 6a, c) . and KL2 domains. KL1 is in the same orientation as in Fig. 1a , whereas KL2 has been superimposed onto KL1 and has thus been reoriented. The eight alternating β -strands (red) and α -helices (cyan/blue) that define the TIM barrel are labelled according to the standard nomenclature for the TIM fold 8 . KL1 and KL2 differ markedly in the conformation of the β 1α 1 loop (wheat). In KL2, this loop protrudes away from the TIM barrel and serves as a receptor binding arm (RBA; Fig. 1) . b, Molecular surfaces of KLrP-glucosylceramide (Glc) (centre; KLrP in yellow), KL1-Glc (left; KL1 in cyan) and KL2-Glc (right; KL2 in blue). Binding of Glc to KL1 and KL2 was simulated by superimposing KL1 and KL2 onto KLrP-Glc. In all cases, Glc is shown as pale grey sticks or surface. The divergent conformation of the β 6α 6 loop (pink) in KL1 almost seals off the entrance to the catalytic pocket, while the divergent conformations of the β 1α 1 (RBA; wheat), β 6α 6 (pink) and β 8α 8 (green) loops in KL2 leave the central barrel cavity in KL2 in a more solvent-exposed state that is less capable of ligating substrate (see also Extended Data Fig. 5 ). c, Glycosidase activity of α -klotho ecto , sialidase and β -glucuronidase. Data are mean and s.d. Dots denote individual data points; n = 3 independent experiments. RU, relative units. Fig. 1a , except that the alternatively spliced region of FGFR1c is highlighted in purple. Red box denotes perimeter of interface between distal tip of α -klotho RBA and the hydrophobic FGFR1c D3 groove. Blue box denotes the perimeter of α -klotho− FGF23 C-tail interface. b, RBA stretches out of the KL2 domain of α -klotho ecto and latches onto the FGFR1c D3 domain. Top, interface between the distal tip of RBA and the D3 groove detailing hydrophobic interactions (grey transparent surfaces). Note that Leu342 (red) from the spliced region of the D3 groove is strictly conserved in 'c' splice isoforms of FGFR1-FGFR3 and FGFR4 and is mutated in Kallmann syndrome 36 . Bottom, close-up view of the extended β -sheet between the RBA-β 1:RBA-β 2 strand pair and the four-stranded β -sheet in D3 (β C′ -β C-β F-β G). This structure forms via hydrogen bonding (dashed yellow lines) between backbone atoms of RBA-β 1 and D3-β C′ . c, Both KL domains of α -klotho ecto participate in tethering of the flexible C-terminal tail of FGF23 (FGF23 C-tail ). FGF23 C-tail residues Asp188-Thr200 thread through the KL1-KL2 cleft and the β -barrel cavity of KL2. Of these residues, Asp188-Leu193 adopt a cage-like conformation that is partially stabilized by intramolecular hydrogen bonds (dashed green lines). Dashed yellow lines denote intermolecular hydrogen bonds; grey transparent surfaces denote hydrophobic interactions. Note that Tyr433 from the KL1 α 7 helix deep inside the KL1-KL2 cleft has a prominent role in tethering the cage-like structure in the FGF23 C-tail formed by Asp188-Leu193. Dashed circle (shown at greater magnification below) denotes the KL1− KL2 interface where residues from both α -klotho domains jointly coordinate a Zn 2+ ion (orange sphere).
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To test the biological relevance of the observed contacts between α -klotho and the FGF23 C-terminal tail, we introduced several mutations into α -klotho TM and FGF23 to disrupt α -klotho-FGF23 binding (Fig. 4c) . Consistent with our structure-based predictions, all α -klotho TM mutants showed an impaired ability to support FGF23 signalling (Fig. 4c) . The FGF23 mutants also exhibited a reduced ability to signal, regardless of whether soluble or membrane-bound α -klotho served as co-receptor (Fig. 4d) . Remarkably, the FGF23(D188A) mutant (which eliminates the intramolecular hydrogen bonds that support cage conformation) was totally inactive, underscoring the importance of the cage-like conformation in the tethering of FGF23 to α -klotho. Notably, tethering of this cage-like structure requires precise alignment of residues from both KL domains deep within the KL1-KL2 cleft (Fig. 3c ), indicating that their correct apposition is critically important for α -klotho co-receptor activity. These structural observations suggest that the bound Zn 2+ ion serves as a prosthetic group in α -klotho by minimizing interdomain flexibility and hence promoting co-receptor activity. Consistent with such a role, mutants of membrane-anchored α -klotho TM carrying alanine in place of two, three or all four Zn 2+ coordinating amino acids ( Fig. 3c) showed a reduced ability to support FGF23 signalling (Fig. 4e) . Together with our data on the effect of RBA deletion, these results corroborate the biological relevance of the crystallographically deduced mode by which α -klotho implements FGF23-FGFR1c proximity and thus confers high binding affinity.
FGF23 signalling is α -klotho-and HS-dependent
Both FGF23 and FGFR1c have a measurable (albeit weak) binding affinity for HS. Because HS is ubiquitously expressed, we wondered whether it participates in the apparent α -klotho ecto -mediated FGF23-FGFR dimerization in our cell-based and in vivo experiments. We therefore analysed the molecular mass of the ternary complex in the absence and presence of increasing molar equivalents of homogenously sulfated heparin hexasaccharide (HS6). Consistent with our previous observations, in the absence of HS6, the ternary complex migrated as a monomeric species 10 with an apparent molecular mass of 150 kDa, in good agreement with the theoretical value for a 1:1:1 complex (160 kDa) (Fig. 5a ). With increasing molar ratios of HS6 to ternary complex, the peak for monomeric ternary complex diminished, while a new peak with a molecular mass of 300 kDa (corresponding to a 2:2:2 FGF23-FGFR1c ecto -α -klotho ecto dimer) appeared and increased in prominence. Excess HS6 beyond a 1:1 molar ratio of HS6 to ternary complex did not lead to any further increase in the amount of dimer complex formed, as judged by the integrated area of the dimer complex peak (Fig. 5a ). We conclude that HS is required for the dimerization of 1:1:1 FGF23-FGFR1c ecto -α -klotho ecto complexes, and that at least a 1:1 molar ratio of HS6 to ternary complex is required for complete dimerization of the complex in solution (Fig. 5a ). To confirm the dependency of dimerization on HS, we introduced mutations into the HS-binding sites of FGFR1c (K160Q/K163Q, FGFR1c
ΔHBS
, and K207Q/R209Q, FGFR1c ΔHBS′ ) and FGF23 (R140A/R143A, FGF23 ΔHBS ). Neither mutating the HS-binding site in FGFR1c nor mutating that site in FGF23 affected the formation of a monomeric 1:1:1 FGF23-FGFR1c-α-klotho complex in solution, demonstrating that α-klothomediated stabilization of the FGF23-FGFR complex is independent of HS. However, ternary complexes containing any of these three mutants failed to dimerize in the presence of HS6 (Fig. 5b) .
Reconstitution experiments in the context of BaF3 cells (an FGFR, α -klotho and HS triple-deficient cell line 29 ) showed that both soluble α -klotho ecto and membrane-bound α -klotho TM required HS to support FGF23-mediated FGFR1c activation in a more physiological context (Fig. 5c ). We also examined the impact of the HS-binding site mutations in FGFR1c and FGF23 on FGFR1c activation by FGF23 in BaF3 cells (Fig. 5d ). In agreement with our solution binding data, activation by FGF23 of HS-binding site mutants of FGFR1c in BaF3 cells was markedly impaired, regardless of whether soluble or membrane-bound α -klotho served as the co-receptor (Fig. 5d) . Similarly, the binding site mutant of FGF23 showed a markedly reduced ability to activate FGFR1c (Fig. 5e ). These in vitro and cell-based analyses unequivocally demonstrate that whereas HS fulfils a dual role in paracrine FGF signalling-enhancing 1:1 FGF-FGFR binding and promoting 2:2 FGF-FGFR dimerization-it shares this task with α -klotho in FGF23 signalling. Thus, α -klotho primarily acts to promote 1:1 FGF23-FGFR1c binding, whereas HS induces the dimerization of the resulting FGF23-FGFR1c-α -klotho complexes.
On the basis of the crystallographically deduced 2:2:2 (Protein Data Bank (PDB) code 1FQ9) 4 and 2:2:1 (PDB code 1E0O) 30 paracrine FGF-FGFR-HS dimerization models, two distinct HS-induced 2:2:2 endocrine FGF23-FGFR1c-α -klotho quaternary dimers can be predicted that differ markedly in the composition of the dimer interface (Extended Data Fig. 8 ). Specifically, in the 2:2:2:1 model, there would be no protein-protein contacts between the two 1:1:1 FGF23-FGFR1c-α -klotho protomers (Extended Data Fig. 8a ). By contrast, in the 2:2:2:2 model, FGF23 and FGFR1c from one 1:1:1 FGF23-FGFR1c-α -klotho protomer would interact with the D2 domain of FGFR1c in the adjacent 1:1:1 FGF23-FGFR1c-α -klotho protomer across a two-fold dimer interface (Extended Data Fig. 8b ). On the basis of the fundamental differences in the composition of the dimer interface between these two models, we introduced mutations into the secondary-receptor-binding site (SRBS) in FGF23 (M149A/N150A/P151A; FGF23 Article reSeArcH (Extended Data Fig. 8b ). Although all of these FGF23 and FGFR1c mutants were able to form ternary complexes with α -klotho ecto , the ternary complexes containing any of the mutated proteins were impaired in their ability to dimerize in the presence of HS6 in solution (Fig. 5f) . Moreover, the FGF23 ΔSRBS mutant showed a markedly diminished ability to activate FGFR1c in BaF3 cells (Fig. 5e) . The loss-of-function effects of these mutations are consistent with a 2:2:2:2 quaternary dimer model (Extended Data Fig. 8b ). Hence, we envision that HS engages the HS-binding sites of FGFR1c and FGF23 in two stabilized 1:1:1 FGF23-FGFR1c-α -klotho ternary complexes to promote the formation of a two-fold symmetric 2:2:2:2 FGF23-FGFR1c-α -klotho-HS dimer (Fig. 5g) . In doing so, HS enhances reciprocal interactions of FGFR1c D2 and FGF23 from one ternary complex with FGFR1c D2 in the other ternary complex, thereby buttressing the dimer (Extended Data Fig. 8b ). This replicates the role that HS has in paracrine FGF signalling 4 . In contrast to HS, α -klotho molecules do not directly participate in the dimer interface (Fig. 5g) , but rather indirectly support HS-induced dimerization by enhancing 1:1 FGF23-FGFR1c binding affinity. Hence, FGF23 seems to strike a fine balance between losing a large amount of HS-binding affinity to enable its endocrine mode of action and retaining sufficient HS-binding affinity to allow HS-mediated dimerization of two 1:1:1 FGF23-FGFR1c-α -klotho complexes. These considerations do not formally exclude the possibility that 2:2:2:2 and 2:2:2:1 quaternary dimers might co-exist as a higher order cluster on the cell surface, as has been proposed previously for paracrine 2:2:2 and 2:2:1 FGF-FGFR1-HS dimers 31 . FGF19 and FGF21, the other two endocrine FGFs, both require β -klotho as an obligate co-receptor to bind and activate cognate FGFRs 32,33 so as to mediate effects that regulate, for example, metabolic pathways involved in bile acid biosynthesis or fatty acid oxidation 34, 35 . On the basis of the structural analysis and supporting cell-based data shown in Extended Data Figs 9 and 10, we propose that β -klotho, similar to α -klotho, functions as a non-enzymatic molecular scaffold to promote signalling by these two FGF hormones.
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No statistical methods were used to predetermine sample size. The experiments were not randomized and, except for the data shown in Extended Data Fig. 7a , b, investigators were not blinded to allocation during experiments and outcome assessment. DNA expression constructs. cDNA fragments encoding full-length human α -klotho, β -klotho and FGFR1c were amplified by PCR and subcloned into the lentiviral transfer plasmids pEF1α -IRES-hygro (α -/β -klotho) or pEF1α -IRESNeo (FGFR1c) using a ligation-independent In-Fusion HD cloning kit (639648, Clontech Laboratories). PCR primers for FGFR1 'c' isotype were designed using NEBaseChanger software version 1.2.6 (New England Biolabs) and primers for KL and KLB (encoding α -klotho and β -klotho, respectively) were designed using the primer design tool for the In-Fusion HD cloning kit (Clontech Laboratories). A cDNA fragment encoding the entire extracellular domain of human α -klotho (residues Met1 to Ser981; α -klotho ecto ) was subcloned into the mammalian expression plasmid pEF1α /myc-His A. DNA fragments for the mature form (that is, without the signal sequence) of human FGF23 (residues Tyr25 to Ile251), human FGF21 (residues His29 to Ser209), and the extracellular D2-D3 region of human FGFR1c (residues Asp142 to Arg365; FGFR1c ecto ), which is both necessary and sufficient for FGF binding, were amplified by PCR and ligated into the cloning sites of the bacterial expression plasmids pET-30a and pET-28a, respectively. Single/ multiple site mutations, loop deletions and truncations were introduced into expression constructs encoding the wild-type proteins using a Q5 Site-Directed Mutagenesis Kit (E0554S, New England Biolabs). The integrity of each expression construct was confirmed by restriction enzyme digestion and DNA sequencing. Information on the constructs is provided in the Supplementary Tables 1 and 2 . Recombinant protein expression and purification. N-acetylglucosaminyltransferase I (GnTI) deficient HEK293S cells (CRL-3022, American Type Culture Collection (ATCC)) were transfected by calcium phosphate co-precipitation with the expression construct encoding α -klotho ecto . G418-resistant colonies were selected for α -klotho ecto expression using 0.5 mg ml −1 G418 (6483, KSE Scientific). The clone with the highest expression level was propagated in DME/F12 medium (SH30023.02, HyClone) supplemented with 10% fetal bovine serum (FBS) (35-010-CV, CORNING), 100 U ml −1 penicillin plus 100 μ g ml −1 streptomycin (15140-122, Gibco), and 0.5 mg ml −1 G418. For protein production, 1 × 10 6 cells were seeded in 25 cm cell culture dishes in 20 ml DME/F12 medium containing 10% FBS and grown for 24 h. Thereafter, the medium was replaced with 25 ml DME/F12 medium containing 1% FBS. Three days later, secreted α -klotho ecto from two litres of conditioned medium was captured on a 5 ml heparin affinity HiTrap column (GE Healthcare) and eluted with a 100 ml linear NaCl gradient (0-1.0 M). Column fractions containing α -klotho ecto were pooled and diluted tenfold with 25 mM Tris pH 8.0 buffer, and the diluted protein sample was loaded onto an anion exchange column (SOUCRE Q, GE Healthcare) and eluted with a 280 ml linear NaCl gradient (0-0.4 M). As a final purification step, SOURCE Q fractions containing α -klotho ecto were concentrated and applied to a Superdex 200 column (GE Healthcare). α -Klotho ecto protein was eluted isocratically in 25 mM HEPES pH 7.5 buffer containing 500 mM NaCl and 100 mM (NH 4 ) 2 SO 4 . A mutant of α -klotho ecto lacking the receptor binding arm (α -klotho ecto/ΔRBA ) was expressed and purified similarly as the wild-type counterpart.
Human wild-type FGF23 and its mutants were expressed in Escherichia coli BL21 DE3 cells. Inclusion bodies enriched in misfolded insoluble FGF23 protein were dissolved in 6 M guanidinium hydrochloride and FGF23 proteins were refolded by dialysis for 2 days at 4 °C against buffer A (25 mM HEPES pH 7.5, 150 mM NaCl, 7.5% glycerol) followed by buffer B (25 mM HEPES pH 7.5, 100 mM NaCl, 5% glycerol). Correctly folded FGF23 proteins were captured on a 5 ml heparin affinity HiTrap column (GE Healthcare) and eluted with a 100 ml linear NaCl gradient (0-2.0 M). Final purification of FGF23 proteins was achieved by cation exchange chromatography (SOURCE S, GE Healthcare) with a 280 ml linear NaCl gradient (0-0.4 M). Human FGFR1c ecto and its mutants were also expressed as inclusion bodies in E. coli BL21 DE3 and refolded in vitro by slow dialysis at 4 °C against the following buffers: buffer A (25 mM Tris pH 8.2, 150 mM NaCl, 7.5% glycerol), buffer B (25 mM Tris pH 8.2, 100 mM NaCl, 5% glycerol), and buffer C (25 mM Tris pH 8.2, 50 mM NaCl, 5% glycerol); dialysis against each buffer was for minimally 12 h. Properly folded FGFR1c proteins were purified by heparin affinity chromatography followed by size-exclusion chromatography as described above. All column chromatography was performed at 4 °C on an AKTA pure 25 l system (GE Healthcare). Crystallization and X-ray crystal structure determination. To facilitate crystallization of the FGF23-FGFR1c ecto -α -klotho ecto complex, we used a proteolytically and structurally more stable FGF23 protein variant, which lacked 46 residues from the FGF23 C-terminus (Cys206 to Ile251) and carried Arg-to-Gln mutations at positions 176 and 179 of the 176-Arg-His-Thr-Arg-179 proteolytic cleavage motif in FGF23. The Arg-to-Gln mutations occur naturally in patients with autosomal dominant hypophosphatemic rickets (ADHR) 37 , and deletion of C-terminal residues Cys206 to Ile251 has no effect on the phosphaturic activity of FGF23 in mice or its signalling potential in α -klotho TM -expressing cultured cells 10 . Thus, the first 26 amino acids (Ser180 to Ser205) of the 72-amino-acidlong C-terminal tail of FGF23, defined as the region past the 176-Arg-His-ThrArg-179 proteolytic cleavage site, comprise the minimal region of the FGF23 C-terminal tail for binding the FGFR1c ecto -α -klotho ecto complex 10 . To prepare the FGF23-FGFR1c ecto -α -klotho ecto complex, its purified components were mixed at a molar ratio of 1.2:1.2:1 and spin-concentrated using an Amicon Ultra-15 concentrator (UFC901024, Merck Millipore). The concentrated sample was applied to a Superdex 200 column (GE Healthcare) and eluted isocratically in 25 mM HEPES pH 7.5 buffer containing 500 mM NaCl and 100 mM (NH 4 ) 2 SO 4 . Column peak fractions were analysed by SDS-PAGE and peak fractions containing the ternary complex were concentrated to 7 mg ml −1 . Concentrated ternary complex was screened for crystallization by sitting drop vapour diffusion. A range of commercially available crystallization screen kits was used: Protein Complex Suite (130715), Classics Suite (130701), Classics II Suite (130723), and Classics Lite Suite (130702) from Qiagen; Crystal Screen (HR2-110), Crystal Screen 2 (HR2-112), Crystal Screen Lite (HR2-128), PEG/Ion Screen (HR2-126), and PEGRx1 (HR2-082) from Hampton Research; and PEG Grid Screening Kit (36436) and Crystallization Cryo Kit (75403) from Sigma-Aldrich. Drops consisting of 100 nl reservoir solution and 100 nl protein complex solution were equilibrated against 100 μ l well volume set up in 96-well plates (Fisher Scientific) using a Mosquito crystallization robot (TTP Labtech). Plates were stored at 18 °C and automatically imaged by Rock Imager 1000 (Formulatrix). Image data were collected and managed using Rock Maker software version 3.1.4.0 (Formulatrix). One crystal hit was obtained after 7 days of plate incubation at 18 °C and one crystallization condition from the Protein Complex Suite (130715, Qiagen) was chosen for optimization using the Additive Screen (HR2-428) from Hampton Research. Crystals were confirmed as protein crystals by UV imaging using Rock Imager 1000 (Formulatrix). Crystal growth in optimized conditions was scaled up in 24-well VDXm plates (Hampton Research) where crystals were grown by hanging drop vapour diffusion. Larger crystals (80 × 76 × 35 μ m) were obtained within 28 days by mixing 1 μ l of protein complex and 1 μ l of crystallization solution. Some of those crystals were dissolved in Lämmli sample buffer after thorough rinsing, and analysed by SDS-PAGE and staining with Coomassie blue to confirm the presence of all three proteins in the ternary complex.
Crystals of ternary complex were briefly soaked in cryo-protective solution consisting of mother liquor supplemented with 25% (w/v) glycerol. These were then mounted on CryoLoops (Hampton Research) and flash-frozen in liquid nitrogen. Crystal screening for X-ray diffraction and diffraction data collection were performed at 100 K on one of the NE-CAT beam lines at the Advanced Photon Source synchrotron of Argonne National Laboratory. X-ray images were recorded with an ADSC Quantum 315 CCD detector with primary oscillations at 100 K, a wavelength of 0.97918 Å, and a crystal-to-detector distance of 420 mm. Crystals of the ternary complex belong to the monoclinic space group C2, and contain one ternary complex molecule in the asymmetric unit. X-ray diffraction data sets were collected to 3.0 Å from native protein crystals, integrated, and scaled using XDS 38 and SCALA 39 from the CCP4 software suite 40 . A clear molecular replacement solution was found for both KL domains using the Phaser module of PHENIX 41 and homology models of KL1 and KL2, which were built with Rosetta software available through the ROBETTA Protein Structure Prediction Server (http://robetta.bakerlab.org). However, the FGF23-FGFR1c component of the ternary complex could not be found even after fixing the coordinates of the partial solution found for the KL domains. Through careful inspection of the crystal lattice and the F o − F c difference and 2F o − F c composite maps generated using the partial model, we succeeded in manually placing an FGF23-FGFR1c D2 portion of the FGF23-FGFR1c complex. This was created using the experimental crystal structures of SOS-bound FGF23 42 (PDB code 2P39) and the FGF2-bound FGFR1c ectodomain 43 (PDB code 1CVS). After a few rounds of refinements, FGFR1c D3 could also be placed manually. Iterative rounds of model building and refinement were carried out using Coot 44 and the Phenix. Refine module of PHENIX 41 . The structure has been refined to 3.0 Å resolution with working and free R-factors of 23.46 and 28.26%, respectively, and good Ramachandran plot statistics. X-ray diffraction data collection and structure refinement statistics are summarized in Extended Data Table 1. The final model comprises residues Glu34 to His977 of human α -klotho ecto , residues Met149 to Ala361 of human FGFR1c ecto and residues Tyr25 to Thr200 of human FGF23. Owing to insufficient electron density, the following residues of the ternary complex could not be built: 1) Leu98 to Ser115 (β 1α 1 loop) of α -klotho ecto KL1, 2) Glu957 to Glu960 (an ADAM protease cleavage site) at the junction between the rigid core of α -klotho ecto KL2 and the flexible extracellular juxtamembrane linker that connects KL2 to the transmem-Article reSeArcH brane helix of α -klotho, 3) the last four residues of the extracellular juxtamembrane linker (Thr978 to Ser981) of α -klotho ecto , 4) the last five C-terminal residues of FGF23 (Pro201 to Ser205), 5) Asp142 to Arg148 N-terminal to the D2 domain of FGFR1c ecto , and 6) Leu362 to Arg365 C-terminal to the D3 domain of FGFR1c ecto . Ordering of the first six N-terminal residues of FGF23 (Tyr25 to Pro30) is influenced by crystal lattice contacts. SEC-MALS. The SEC-MALS instrument setup consisted of a Waters Breeze 2 HPLC system (Waters), a miniDAWN-TREOS 18-angle static light scattering detector with built-in 658.0-nm wavelength laser (Wyatt Technology Corp.), and an Optilab rEX refractive index detector (Wyatt Technology Corp.). A Superdex 200 10/300 GL column (GE Healthcare) was placed in-line between the HPLC pump (Waters 1525) and the HPLC UV (Waters 2998 Photodiode Array), laser light scattering, and refractive index detectors. Light scattering and refractive index detectors were calibrated following the manufacturer's guidelines. The refractive index increment (dn/dc), in which n is the refractive index and c is the concentration of the mixture of DDM and CHS in 20 mM Tris-HCl pH 8.0 buffer containing 300 mM NaCl, was determined offline using an Optilab T-rEX refractive index detector. Monomeric bovine serum albumin (23210, Thermo Scientific) was used as part of routine data quality control.
At least 60 ml of 25 mM HEPES pH 7.5 buffer containing 150 mM NaCl were passed through the system at a flow rate of 0.5 ml min −1 to equilibrate the Superdex 200 10/300 GL column and establish stable baselines for light scattering and refractive index detectors. Purified α -klotho ecto , FGFR1c ecto (wild type or mutant), and FGF23 (wild type or mutant) proteins were mixed at a molar ratio of 1:1:1 and concentrated to 12.5 μ M. Protein samples (50 μ l) with a molar equivalent of a heparin hexasaccharide (HO06, Iduron) were injected onto the gel filtration column, and the column eluent was continuously monitored for 280 nm absorbance, laser light scattering, and refractive index. In a separate set of experiments, 50 μ l of 1:1:1 FGF23-FGFR1c ecto -α -klotho ecto ternary complex at 12.5 μ M concentration was mixed with heparin hexasaccharide at molar ratios of 1:0.25, 1:0.5, 1:1 or 1:2, and the mixtures were injected onto the gel filtration column. As a control, 50 μ l of ternary complex without added heparin hexasaccharide were run on the column. In yet another set of experiments, α -klotho ecto (wild type or mutant) and FGFR1c ecto were mixed at a molar ratio of 1:1, and 50 μ l of concentrated protein mixtures were injected onto the gel filtration column. 50 μ l of concentrated α -klotho ecto (wild type or mutant) alone were run as a control in these experiments. The analyses were performed at ambient temperature. Data were collected every second at a flow rate of 0.5 ml min −1
. Laser light scattering intensity and eluent refractive index (concentration) data were adjusted manually for the volume delay of UV absorbance at 280 nm, and were processed using ASTRA software (Wyatt Technology Corp.). A protein refractive index increment (dn/dc value) of 0.185 ml g −1 was used for molecular mass calculations. Cell line culture and stimulation and analysis of protein phosphorylation. HEK293 cells (a gift from A. Mansukhani, identified by morphology check under microscope, mycoplasma negative in DAPI) were maintained in DMEM medium (10-017-CV, CORNING) supplemented with 10% FBS, 100 U ml −1 of penicillin and 100 μ g ml −1 streptomycin. HEK293 cells naturally express multiple FGFR isoforms including FGFR1c, FGFR3c and FGFR4, but lack α -klotho or β -klotho co-receptors. BaF3 cells (a gift from S. Byron, identified by morphology check under microscope, mycoplasma negative in DAPI), an IL-3-dependent haematopoietic pro B cell line, were cultured in RPMI 1640 medium (10-040-CV, CORNING) supplemented with 10% FBS, 100 U ml −1 of penicillin, 100 μ g ml
streptomycin and 5 ng ml −1 mouse IL-3 (#GFM1, Cell Guidance Systems). BaF3 cells do not express FGFRs, α -/β -klotho co-receptors, or HS cofactors, and hence are naturally non-responsive to FGFs. However, via controlled ectopic expression of FGFRs and klotho co-receptors and exogenous supplementation with soluble HS, these cells can be forced to respond to FGF stimulation. As such, the BaF3 cell line has served as a powerful tool for reconstituting FGF-FGFR cell surface signal transduction complexes to dissect the molecular mechanisms of paracrine and endocrine FGF signalling 29, 45, 46 . Stable or transient expression of full-length (transmembrane) human α -klotho, β -klotho, FGFR1c, and mutants of these proteins in HEK293 or BaF3 cells was achieved using lentiviral vectors. To generate lentiviral expression vectors, HEK293 cells were seeded at a density of about 8 × 10 5 in 10 cm cell culture dishes and co-transfected by calcium phosphate co-precipitation with 8 μ g of lentiviral transfer plasmid encoding wild-type or mutant α -klotho, β -klotho or FGFR1c, 1.6 μ g of pMD2.G envelope plasmid, and 2.5 μ g of psPAX2 packaging plasmid. Fresh medium was added to the cells for a 3-day period after transfection. Cell culture supernatant containing recombinant lentivirus particles was collected and used to infect 2 × 10 5 HEK293 or BaF3 cells in the presence of polybrene (5 μ g ml
; 134220, Santa Cruz Biotechnology). Stable transfectants were selected using hygromycin (1 mg ml
, ant-hg-1, InvivoGen) or G418 (0.5 mg ml −1
, 6483, KSE Scientific). For transient protein expression, 2 × 10 5 HEK293 cells were plated in 6-well cell culture dishes and on the following day, the cells were infected with recombinant lentivirus in the presence of polybrene (16 μ g). For cell stimulation studies, unmodified and stably transfected HEK293 cells were seeded in 6-well cell culture plates at a density of 4 × 10 5 cells per well and maintained for 24 h in cell culture medium without FBS. In the case of transiently transfected HEK293 cells, medium containing lentivirus particles was removed from the cells after incubation for approximately 12 h, and the cells were also serum-starved for 24 h. Stably transfected BaF3 cells were seeded in 10 cm cell culture dishes at a density of 6 × 10 6 cells and serum-starved for 6 h. Unmodified HEK293 cells were stimulated for 10 min with wild-type or mutant FGF23 both in the presence and absence of wild-type or mutant α -klotho ecto . HEK293 cells stably or transiently expressing wild-type α -klotho TM or its mutants were stimulated with wild-type or mutant FGF23 alone. In one set of experiments, HEK293 cells expressing wild-type α -klotho TM were pretreated with α -klotho ecto for 10 min before stimulation with wild-type FGF23. BaF3 cells expressing wildtype or mutant FGFR1c were stimulated with wild-type or mutant FGF23 in the presence or absence of α -klotho ecto and heparin. BaF3 cells co-expressing wild-type α -klotho TM and wild-type or mutant FGFR1c were stimulated with wildtype or mutant FGF23 in the presence of heparin. BaF3 cells co-expressing wildtype FGFR1c and wild-type or mutant β -klotho TM were stimulated with wild-type FGF21 in the presence or absence of heparin.
After stimulation, cells were lysed, and lysate samples containing approximately 30 μ g total cellular protein were electrophoresed on 12% SDS-PAGE and electrotransferred onto a nitrocellulose membrane. The membrane was blocked for 1 h at ambient temperature in Tris-buffered saline pH 7.6 containing 0.05% Tween-20 and 5% BSA (BP1600-100, Fisher BioReagents). Rabbit monoclonal antibodies to phosphorylated ERK1/2 (4370, Cell Signaling Technology) and total (phosphorylated and unphosphorylated) ERK1/2 (4695, Cell Signaling Technology) were diluted 1:2,000 and 1:1,000, respectively, in blocking buffer. After overnight incubation at 4 °C with one of these diluted antibodies, the blot was washed with Tris-buffered saline pH 7.6 containing 0.05% Tween-20, and then incubated at ambient temperature for 30 min with 1:10,000-diluted IRDye secondary antibody (926-32211 (goat anti-rabbit), LI-COR). After another round of washing with Tris-buffered saline pH 7.6 containing 0.05% Tween-20, the blot was imaged on an Odyssey Fc Dual-mode Imaging System (LI-COR). α-Klotho treatment of mice and serum, urinary phosphate analysis. Mice of the strain 129/Sv (Charles River Laboratories) were housed in a room with a temperature of 22 ± 1 °C and a 12 h:12 h light/dark cycle, and had ad libitum access to tap water and Teklad global 16% rodent diet (Envigo). Ten female and ten male 6-week-old mice of each gender were assigned to receive either recombinant α -klotho ecto protein diluted in isotonic saline (0.1 mg kg −1 body weight) or protein diluent only (buffer control). Mice were placed in metabolic cages for a one-day acclimation, and returned to the cages for 24-h urine collection after intraperitoneal injection of α -klotho ecto protein or buffer control. After urine collection, mice were placed under isofluorane anaesthesia, and blood was drawn from the retro-orbital sinus and transferred into tubes containing a few drops of sterile solution of heparin (Sagent Pharmaceuticals). After centrifugation at 3,000g at 4 °C for 5 min, supernatant plasma was taken out of the tubes and stored at − 80 °C. Blood and urine samples were also collected before injection of α -klotho ecto or buffer control. Phosphate and creatinine concentrations in plasma and urine were measured using a Vitros Chemistry Analyzer (Ortho-Clinical Diagnosis) and a P/ACE MDQ Capillary Electrophoresis System equipped with a photodiode detector (Beckman-Coulter), respectively. The Mouse Metabolic Phenotyping Core Facility at UT Southwestern Medical Center carried out the measurements of these analytes.
In a separate set of experiments, 10-to 12-week-old mice were given an intraperitoneal injection of wild-type α -klotho ecto (0.1 mg kg −1 body weight), RBA deletion mutant, α -klotho ecto/ΔRBA (0.1 mg kg −1 body weight), or protein diluent only (three female and three male mice per group), and blood and urine samples were collected for measurement of phosphate and creatinine as described above. In yet another set of experiments, 10-to 12-week-old mice were injected intraperitoneally with 0.1 mg kg −1 body weight of wild-type α -klotho ecto (two female and one male mice), mutant α -klotho ecto/ΔRBA (two female and two male mice), or protein diluent only (two female and one male mice), and kidneys were obtained from the mice under isofluorane anaesthesia four hours after the injection. Total RNA was extracted from the kidneys using RNAeasy kit (Qiagen), and Egr1 mRNA levels were quantified by quantitative PCR (qPCR) with cyclophilin (also known as Ppia) as a control. Template cDNA for the PCR was generated using SuperScript III First Strand Synthesis System (Invitrogen) and oligo-(dT) primers. PCR primers for Egr1 were 5′ -GAGGAGATGATGCTGCTGAG-3′ and 5′ -TGCTGCTGCTGCTATTACC-3′ . PCR primers for cyclophilin were 5′ -GTCTCTTTTCGCCGCTTGCT-3′ and 5′ -TCTGCTGTCTTTGGAACTTTGTCTG-3′ . qPCR was performed in triplicate for each kidney RNA sample. Except for Egr1 expression analysis, data were analysed by paired Student's t-test. All studies in mice were approved by the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center and conducted following the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Enzymatic assay. To examine α -klotho ecto for glycoside-hydrolase activity, 4-methylumbelliferyl-β -d-xylopyranoside (M7008, Sigma-Aldrich), 4-methylumbelliferyl-β -d-glucuronide (474427, Sigma-Aldrich) and 4-methylumbelliferyl-α -d-N-acetylneuraminic acid (69587, Sigma-Aldrich) were selected as substrates and commercially available recombinant neuraminidase (#10269611001, Roche Diagnostics GmbH) and β -Glucuronidase (#G0251, SigmaAldrich) were used as positive controls. 20 μ g of α -klotho ecto or the control enzymes were added into reaction buffer (0.1 M sodium citrate buffer, pH 5.6, 0.05 M NaCl, 0.01% Tween 20) containing 0.5 mM substrate at a final volume of 100 μ l, and the reaction mixtures were incubated at 37 °C for 2 h. Enzymatic activity was assessed by quantifying fluorescence intensity of released 4-methylumbelliferone at an excitation wavelength of 360 nm and an emission wavelength of 450 nm using a FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices). and its soluble isoform α -klotho ecto generated by an ectodomain shedding in the kidney 16 . KL1 and KL2 are tandem domains with homology to family 1 glycosidases 8 . b, Representative immunoblots of phosphorylated ERK (top) and total ERK (bottom; sample loading control) in total HEK293 cell lysates (n = 3 independent experiments). Top, lysates from untransfected HEK293 cells that were pre-treated with a fixed α -klotho ecto concentration (10 nM) and then stimulated with increasing FGF23 concentrations, and lysates from HEK293-α -klotho TM cells treated with increasing concentrations of FGF23 alone.
Bottom, lysates from HEK293-α -klotho TM cells that were pre-treated with increasing α -klotho ecto concentrations and then stimulated with a fixed FGF23 concentration. c, Plasma phosphate, fractional excretion of phosphate, and phosphate excretion rate in wild-type mice before and after a single injection of α -klotho ecto (0.1 mg kg −1 body weight) or isotonic saline alone (buffer). Circles denote mean values; error bars denote s.d. n = 10 mice per group. * P < 0.05, paired Student's t test. d, Relative Egr1 mRNA levels in the kidney of wild-type mice after a single injection with α -klotho ecto (0.1 mg kg −1 body weight) or isotonic saline alone (buffer). Data are mean and s.d. n = 3 mice per group. The same batch of α -klotho ecto protein was used in the experiments shown in b-d. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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